Rights Issue To Raise Up To $3.44 Million
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Product Development Market Update
- ArTiMist Regulatory Update
- Appendix 4C Amended
- SUDA Signs Agreement With Mitsubishi Tanabe
- ZLD to Invest in Development of Oral Spray Formulations
Later from Arovella Therapeutics
- Prospectus For Renounceable Pro Rata Offer
- SUDA SIgns Binding Term Sheet With Cann Pharmaceutical
- Rights Issue Closes Significantly Oversubscribed
- Supplementary Prospectus
- European Anagrelide Cancer Patent
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics